TABLE 1.
Characteristics of non‐small cell lung cancer patients treated with platinum‐based chemotherapy
| Variables | All patients (n = 212) | Treatment response | |||
|---|---|---|---|---|---|
| PR (n = 52) | SD (n = 112) | PD (n = 48) | p value | ||
| Age, yr | |||||
| <66 | 101 (47.6) | 21 (40.4) | 61 (54.5) | 19 (39.6) | 0.109 |
| ≥66 | 111 (52.4) | 31 (59.6) | 51 (45.5) | 29 (60.4) | |
| Sex | |||||
| Male | 155 (73.1) | 40 (77.0) | 85 (75.9) | 30 (62.5) | 0.167 |
| Female | 57 (26.9) | 12 (23.0) | 27 (24.1) | 18 (37.5) | |
| Smoking habit | |||||
| Never | 43 (20.3) | 8 (15.3) | 21 (18.8) | 14 (29.2) | 0.194 |
| Current + former | 169 (79.7) | 44 (84.7) | 91 (81.2) | 34 (70.8) | |
| ECOG PS | |||||
| 0–1 | 161 (75.9) | 32 (61.5) | 93 (83.0) | 36 (75.0) | 0.011 |
| ≥2 | 51 (24.1) | 20 (38.5) | 19 (17.0) | 12 (25.0) | |
| Histology | |||||
| SQC | 78 (36.8) | 23 (44.2) | 39 (34.8) | 16 (33.3) | 0.454 |
| ADC | 114 (53.8) | 23 (44.2) | 65 (58.1) | 26 (54.2) | |
| Others | 20 (9.4) | 6 (11.6) | 8 (7.1) | 6 (12.5) | |
| EGFR mutation | |||||
| No | 105 (49.5) | 20 (38.5) | 64 (57.1) | 21 (43.8) | 0.040 |
| Yes | 38 (18) | 8 (15.4) | 22 (19.7) | 8 (16.7) | |
| Not tested | 69 (32.5) | 24 (46.1) | 26 (23.2) | 19 (39.5) | |
| Stage | |||||
| III | 65 (30.7) | 16 (30.8) | 33 (29.5) | 16 (33.4) | 0.888 |
| IV | 147 (69.3) | 36 (69.2) | 79 (70.5) | 32 (66.6) | |
| Chemotherapy agent | |||||
| Irinotecan/cisplatin | 129 (60.8) | 32 (61.5) | 62 (55.3) | 35 (72.9) | 0.354 |
| Gemcitabine/cisplatin | 32 (15.2) | 7 (13.5) | 19 (17.0) | 6 (12.5) | |
| Pemetrexed/cisplatin | 31 (14.6) | 6 (11.5) | 21 (18.8) | 4 (8.3) | |
| Others | 20 (9.4) | 7 (13.5) | 10 (8.9) | 3 (6.3) | |
Abbreviations: ADC, adenocarcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; PD, progressive disease; PR, partial response; SD, stable disease; SQC, squamous cell carcinoma.